Is this a HIGH dose?

It's the question I'm asked most often, and it deserves a real answer rather than reassurance. Here is where the numbers actually sit.

If you've read that women need more estrogen than they're usually given, that can sound alarming. More than standard sounds like a lot when nobody has told you where standard sits.

So let's start with what your own body did before anything changed.

A woman with working ovaries doesn't hold her estradiol steady. It moves across the month, and that movement is the point.

In the first days of your period it sits low, around 30 to 40 picograms per millilitre. Those tend to be the days you feel least like yourself, which is not a coincidence. Then it climbs. Just before you ovulate it peaks, often somewhere between 200 and 350. Afterwards it settles near 150 for the second half of the month.

​

Estradiol across one ovulatory cycle, against what a standard transdermal patch delivers.
​

A common estradiol patch produces a blood level of roughly 40. Double the patch strength, which is more than most women are ever prescribed, and you reach about 75.
​

Read that against the chart. A woman on a standard patch is being held at approximately the level her body produced on the second day of her period, indefinitely. And when she says it isn't working, the conversation is usually about whether hormone therapy suits her, rather than about the arithmetic.

She isn't failing to respond to treatment. She's responding exactly as you'd expect to being held at her lowest point of the month, permanently.

It means higher than 40. That's all it has ever meant.

Most women feel well somewhere between 100 and 250. That is the middle of a normal cycle. If a thirty-four-year-old had blood drawn on day ten and came back at 160, nobody would blink.

The aim is not more than your body made. It's what your body made.

This is the fair version of the worry, so here is the honest answer.

If the amount of estrogen drove breast cancer risk, you would expect to see risk rise steadily with dose. That pattern has not been found. The Million Women Study, one of the largest datasets ever assembled on this question, reported that risk varied little by estrogen dose.

Patterns like that do exist for other things. Alcohol raises breast cancer risk by roughly 7 to 9 percent per daily drink, with no level at which it stops mattering. Body weight raises it by about 12 percent per five BMI (body mass index) units.
​

Here is what that looks like side by side.
​

Extra or fewer breast cancers per 1,000 women aged 50–59 over roughly five years. The intervention women are warned about most urgently is on the protective side. The largest single mover is body weight, which rarely comes up in the conversation at all.

One caution, because I would rather be careful than impressive. I am not telling you estrogen prevents breast cancer. What I am telling you is that the dose relationship everyone assumes exists has not been demonstrated, and the direction of the evidence is not what most women have been led to believe.
​

Women are counselled about breast cancer above everything else. Here is where it actually sits among the things you are likely to face.
​

Lifetime chance a woman in the United States develops each condition. Starting ages differ between studies. Estrogen has evidence behind it on most of this list.

None of that is usually mentioned in the same room as the 13 percent.
​

This part surprises most people, including many physicians.

Treating until your symptoms resolve is not aggressive medicine. It is the recommendation, written down, by the bodies that write recommendations. What hasn't caught up is everyday practice.

Much of the risk attributed to the amount of estrogen is really about how it gets in. Swallowed estrogen passes through your liver first, and your liver responds by making more clotting factors. That is where the clot signal comes from. Non-oral estradiol has not been shown to add measurable clot or stroke risk.

No large trial has followed women on sustained physiologic estradiol for decades with hard outcomes. That study doesn't exist, and I won't pretend otherwise.

What exists is solid evidence for estradiol as a molecule, evidence that non-oral delivery avoids the clot signal, the absence of any demonstrated dose gradient, and the fact that these are levels your own body maintained for thirty years without anyone calling it a risk.

And notice that the same gap applies to the alternative. There is no trial showing that holding a woman at 40 for twenty years is both safe and effective. It has never been tested. It was arrived at under a doctrine that has since been retired, and treated as the careful choice ever since simply because it's smaller.
​

Smaller is not the same as safer. A dose too low to protect your bones isn't conservative. It's a dose that doesn't work.

Figures drawn from the Million Women Study (Lancet 2003), the British Menopause Society and Women's Health Concern breast cancer risk materials, Chlebowski et al. (JAMA 2020), Chen et al. (Int Urogynecol J 2021), Cauley et al. (JAMA 2003), Boardman et al. (Cochrane 2015), Salpeter et al. (J Gen Intern Med 2004), and lifetime risk estimates compiled from Foxman (2002), Wilkins et al. (2012), the US Surgeon General (2004), Fang et al. (2025), the American Cancer Society, and Bell et al. (2016). Guidance references: The Menopause Society 2022 Hormone Therapy Position Statement; FDA labeling changes 2025–2026; NICE NG23.

This is general information about how hormone dosing and risk are discussed, not medical advice, and it isn't a substitute for a conversation with your own clinician. Decisions about whether hormone therapy is right for you, and at what dose, depend on your history and should be made together with a physician who knows it.